HPV vaccination and screening for cervical cancer in young women in Sweden

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of offering HPV vaccination and screening simultaneously to women aged 22-27 in Sweden. It aims to determine if this approach can lead to a faster reduction in HPV infections at the population level. The study utilizes the Gardasil 9 vaccine, which protects against multiple HPV types responsible for the majority of cervical cancer cases. Participants will be screened for HPV and offered vaccination regardless of their previous vaccination history or screening results.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Eligible women will include resident women within the age range of 22-26, who have not opted out of the screening program and who consent to participate in the study.

Women who respond to the invitation and attend screening will be screened with HPV testing by the current routine practise. Women who consent to participate will also be offered HPV vaccination. The HPV vaccine (Gardasil 9) will be offered regardless of whether the woman reports having had prior vaccination with a first-generation vaccine (Gardasil 4) and regardless of screening test result.

Exclusion Criteria:

1. Known history of severe allergic reaction or hypersensitivity to any of the components of the HPV vaccine.For GARDASIL 9: Amorphous aluminium hydroxyphosphate sulphate adjuvant, Sodium chloride, L-histidine, Polysorbate 80 or Sodium borate
2. Known history of immune-related disorders
3. Current acute severe febrile illness, except for minor infections such as a cold, mild upper respiratory infection or low-grade fever.
4. Administration of immunoglobulin or blood-derived products within 6 months prior to scheduled HPV vaccine first dose
5. Current pregnancy (reported)
6. Women with a total hysterectomy

Where it's running

• Cancer prevention, screening, and counseling unit, Regional Cancer Center of Stockholm-Gotland
  Stockholm, Sweden Recruiting

Study contacts

• Study coordinator: Miriam Elfström, PhD
• Email: miriam.elfstrom@sll.se
• Phone: +46703816277

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• At-home HPV self-collection kits for cervical cancer screening

  We are testing different ways to give at-home HPV self-collection kits to under-screened people aged 25–65 to see if more of them complete cervical cancer screening and follow-up.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT07453459

• CHW4CervixHealth: HPV self-collection kits with community health workers

  This project will test whether giving self-collection HPV kits during community workshops led by community health workers helps increase screening among under-screened women aged 25–65 and will first compare kit results to clinical Pap smears.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07336134

• Same-day HPV screen-and-treat for women with HIV in La Romana

  This project will test whether offering same-day HPV screening and immediate treatment improves detection and treatment completion for Spanish-speaking women living with HIV in La Romana, Dominican Republic.

  Recruiting Columbia University · La Romana · NCT07225530

• Using a portable colposcope for cervical cancer screening

  This study is testing a portable device to help screen women for cervical cancer and HPV in Kenya, aiming to improve diagnosis and treatment options.

  Recruiting Duke University · Nairobi · NCT06458062

• Comparing two treatments for cervical cancer risk reduction in women living with HIV in Mozambique

  This study is testing two different treatments for pre-cancerous cervical lesions in women living with HIV in Mozambique to see which one works better in getting rid of high-risk HPV.

  Recruiting Instituto Nacional de Saúde, Mozambique · Maputo · NCT06326294

• Non-invasive plasma treatment for HPV infections

  This study is testing a new non-invasive plasma treatment to see if it can help people clear HPV infections without causing any cervical issues.

  Recruiting University Hospital Tuebingen · Tübingen · NCT06291311

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.